ABOUT US

Management Team

Professor Qian Cheng
Chief Scientist

Professor Cheng Qian- Chief Scientist

The well-known founder of the industry and academia

Director of National International Joint Research Center for Precision Medical Biotherapy of Ministry of Science and Technology

Chief Scientist of the Key Research and Development Program of the Ministry of Science and Technology

Chairman of the Precision Biotherapy Committee of China pharmaceutical quality management association

The winner of Chongqing's "One-Hundred Talents Program", the first batch of "Scientific and Technological Innovation Talents" and "the first batch of One-hundred Leading Talents"

achievements in scientific research:

Presided over the completion of a total of 40 overseas and domestic research projects

Obtained 21 international invention patents and 16 domestic invention patents

More than 170 SCl papers were published, with the total impact factor exceeding 1,000.

Industry experience:

Engaged in basic, transformation and clinical experimental research of tumors for nearly 30 years.

Study the molecular mechanism of tumor microenvironment regulating cancer metastasis and recurrence, and explore new targets for tumor therapy

Developing new strategy of gene therapy for cancer and taking the lead in proposing a new concept of "virus-gene" therapy for cancer

Opening up a new direction of cellular immunotherapy, a number of new cancer cell therapy technologies, approved and successfully treated more than 2,000 cancer patients

Educational background

Education:

Doctor, University of Navarre, Spain

Previous teaching posts:

Director, Biological Treatment Center, Southwest Hospital, Third Military Medical University

Professor, Peking University Hospital of Clinical Oncology

Professor, Center for Applied Medical Research, Spain, and Director of Biotherapy Research Office, University of Navarre

Professor Jesus Prieto
Foreign Chief Scientist

Professor Jesus Prieto- Foreign Chief Scientist

Published more than 460 research papers, and was awarded the "Excellent Achievement Award" by European Association For The Study Of The Liver in 2013.

Professor Sean Hall
Overseas Clinical Director

Professor Sean Hall- Overseas Clinical Director

He has published more than 30 academic papers, and has rich clinical research experience in the field of tumor cell therapy and lung regenerative medicine.

Zhou Zhengjun
Deputy General Manager

Deputy General Manager

More than 30 years of working experience, with administrative operation, management and sales experience in large state-owned enterprises, private enterprises and listed companies.

Dr. Luo Yongli
Deputy General Manager & BD Director

Dr. Luo Yongli- Deputy General Manager & BD Director

15+ years of working experience, with experience in clinical tumor treatment, hospital drug clinical trial management and operation management


Sun Xiaobo
Deputy General Manager & Quality Director

Sun Xiaobo - Deputy General Manager & Quality Director

Over 30 years of experience in pharmaceutical production quality management

Dr. Shen Junjie
Clinical Director

Dr. Shen Junjie-Clinical Director

More than 15 years of working experience, focusing on gene, cell technology research and development, cell drug pharmacology and toxicology evaluation experience, etc., presided over 3 national projects, and participated in more than 10 national projects as the backbone.

Dr. Yang Zhi
Technical Director

Dr. Yang Zhi- Technical Director

More than 15 years of experience, focusing on cell therapy, gene, virus combination therapy experience, etc., presided over or participated as the backbone of more than 10 national projects.

Dr. Zhang Qianzhen
Registration Director

Dr. Zhang Qianzhen- Registration Director

More than 10 years of experience, focusing on clinical-grade plasmid, virus, vector and cell product quality management experience, etc.

The company's R&D team is one of the earliest teams in the world to carry out cell therapy research on malignant tumor. They have a deep understanding and accumulation of this field. The core post members have a solid theoretical foundation in the field of cell therapy technology research and more than 15 years of practical experience in the clinical field of product preparation.

The members of R&D team took the lead in proposing the "virus-gene" combination therapy theory internationally, and achieved the powerful combination therapy effect of virus oncolysis and genes.

The company's R&D team adopts the expert talent introduction mechanism of "international introduction, domestic alliance, and enterprise cultivation", gathers global technical resources, and builds an international R&D team.

Prev